251 related articles for article (PubMed ID: 36982839)
1. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839
[TBL] [Abstract][Full Text] [Related]
2. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
[TBL] [Abstract][Full Text] [Related]
4. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
[TBL] [Abstract][Full Text] [Related]
6. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
7. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant.
Jimenez Jimenez A; Komanduri K; Brown S; Wang T; Pereira D; Goodman M; Beitinjaneh A; Lekakis L; Chinapen S; Devlin S; Ponce D; Sauter C; Perales MA; Shaffer BC
Blood Adv; 2022 Aug; 6(15):4491-4500. PubMed ID: 35793451
[TBL] [Abstract][Full Text] [Related]
8. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
[TBL] [Abstract][Full Text] [Related]
9. Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.
Shouman MT; Mansour OM; El Gammal MM; Abdel-Fattah RM; Samra MA; Elhaddad AM; Maher MA; Mahmoud HK
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):379-387. PubMed ID: 37363983
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
11. Lower Incidence of Cytomegalovirus Reactivation Following Post-Transplantation Cyclophosphamide HLA-Mismatched Unrelated Donor Transplantation.
Camargo JF; Ebisu Y; Jimenez-Jimenez A; Natori Y; Moroz I; Morris MI; Alencar M; Anderson AD; Lekakis L; Beitinjaneh A; Goodman M; Wang T; Pereira D; Komanduri KV
Transplant Cell Ther; 2021 Dec; 27(12):1017.e1-1017.e7. PubMed ID: 34543769
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation.
Bailén R; Kwon M; Pascual-Cascón MJ; Ferrà C; Sanz J; Gallardo-Morillo A; García-Sola A; Torrent A; Jiménez-Lorenzo MJ; Piñana JL; Montoro J; Oarbeascoa G; Dorado N; Gómez-Centurión I; Muñoz C; Martínez-Laperche C; Anguita J; Buño I; Díez-Martín JL;
Ann Hematol; 2021 Feb; 100(2):541-553. PubMed ID: 33140137
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
Battipaglia G; Labopin M; Kröger N; Vitek A; Afanasyev B; Hilgendorf I; Schetelig J; Ganser A; Blaise D; Itälä-Remes M; Passweg JR; Bonifazi F; Finke J; Ruggeri A; Nagler A; Mohty M
Blood; 2019 Sep; 134(11):892-899. PubMed ID: 31270102
[TBL] [Abstract][Full Text] [Related]
16. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Penack O; Abouqateb M; Peczynski C; Boreland W; Gülbas Z; Gedde-Dahl T; Castilla-Llorente C; Kröger N; Eder M; Rambaldi A; Bonifazi F; Blau IW; Stelljes M; Dreger P; Moiseev I; Schoemans H; Koenecke C; Peric Z
Blood Cancer J; 2024 Mar; 14(1):45. PubMed ID: 38485723
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
18. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
[TBL] [Abstract][Full Text] [Related]
20. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia.
Huang Z; Yan H; Teng Y; Shi W; Xia L
Front Immunol; 2022; 13():1017850. PubMed ID: 36458000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
